Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 14, 2021

Primary Completion Date

July 1, 2023

Study Completion Date

July 1, 2023

Conditions
Pancreatic CancerChronic Pancreatitis
Interventions
DRUG

Lidocaine IV

Administration of IV lidocaine will take place according to the standard protocol as is currently already used in daily clinical practice. First, a lidocaine bolus of 1.5mg/kg is administered, followed by a continuous infusion of 1.5mg/kg/hour. When no pain relief is noticed, each 15 minutes the dose is raised with 1ml up to a maximum of 2mg/kg/hour. If again no pain relief is noticed, the anesthesiologist is consulted. When the anesthesiologist agrees, and no side effects occur, lidocaine infusion can be increased up to a maximum of 2.5mg/kg/hour, with a maximum of 250mg/hour. When there is a pain response - pain is reduced with at least two NRS points or 30% from baseline - that dose is administered for two hours continuously. Following treatment the patient will be observed for an hour before leaving the hospital or recovery unit, again, all according to current daily clinical practice.

Trial Locations (1)

1105 AZ

Amsterdam UMC, locatie AMC, Amsterdam

All Listed Sponsors
lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT05906615 - Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis | Biotech Hunter | Biotech Hunter